100 related articles for article (PubMed ID: 7061860)
21. The many effects of complement C3- and C5-binding proteins in renal injury.
Puri TS; Quigg RJ
Semin Nephrol; 2007 May; 27(3):321-37. PubMed ID: 17533009
[TBL] [Abstract][Full Text] [Related]
22. Radioimmunoelectrophoresis, a sensitive method for detecting cleavage of the fifth component of human complement (C5).
Perez HD; Ong R; Banda D; Goldstein IM
J Immunol Methods; 1983; 56(1):55-62. PubMed ID: 6827091
[TBL] [Abstract][Full Text] [Related]
23. Posttransplant ischemia-reperfusion injury in transplanted heart is prevented by a minibody to the fifth component of complement.
Ferraresso M; Macor P; Valente M; Della Barbera M; D'Amelio F; Borghi O; Raschi E; Durigutto P; Meroni P; Tedesco F
Transplantation; 2008 Nov; 86(10):1445-51. PubMed ID: 19034016
[TBL] [Abstract][Full Text] [Related]
24. [Mechanisms of development and progression of ARDS and the humoral responses].
Suwa K
Kokyu To Junkan; 1983 Sep; 31(9):931-7. PubMed ID: 6318286
[No Abstract] [Full Text] [Related]
25. Haemodialysis induced activation of complement relates also to individual responsiveness.
Knudsen F; Nielsen AH; Pedersen JO; Jersild C
Int J Artif Organs; 1985 Jul; 8(4):233-4. PubMed ID: 4055100
[No Abstract] [Full Text] [Related]
26. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation.
Kroshus TJ; Rollins SA; Dalmasso AP; Elliott EA; Matis LA; Squinto SP; Bolman RM
Transplantation; 1995 Dec; 60(11):1194-202. PubMed ID: 8525509
[TBL] [Abstract][Full Text] [Related]
27. Effects of complement activation on the expression of CD59 by human mesangial cells.
Shibata T; Kohsaka T
J Immunol; 1995 Jul; 155(1):403-9. PubMed ID: 7541422
[TBL] [Abstract][Full Text] [Related]
28. A sensitive ELISA for the quantitation of human C5a in blood plasma using a monoclonal antibody.
Schulze M; Götze O
Complement; 1986; 3(1):25-39. PubMed ID: 3743034
[TBL] [Abstract][Full Text] [Related]
29. Monoclonal antibodies directed against human C5 and C8 block complement-mediated damage of xenogeneic cells and organs.
Rollins SA; Matis LA; Springhorn JP; Setter E; Wolff DW
Transplantation; 1995 Dec; 60(11):1284-92. PubMed ID: 8525523
[TBL] [Abstract][Full Text] [Related]
30. Partial characterization of procomplementary activity of porcine serum and its relationship to the fifth component of complement.
Jensen MT; Stone SS
Am J Vet Res; 1981 Dec; 42(12):2071-3. PubMed ID: 6176150
[TBL] [Abstract][Full Text] [Related]
31. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
[TBL] [Abstract][Full Text] [Related]
32. Quantitation and stability of the fifth component of complement (C5) in bronchoalveolar lavage fluids obtained from non-human primates.
Kolb WP; Kolb LM; Wetsel RA; Rogers WR; Shaw JO
Am Rev Respir Dis; 1981 Feb; 123(2):226-31. PubMed ID: 7235362
[TBL] [Abstract][Full Text] [Related]
33. A high molecular weight chemoattractant generated from C5 by ultracentrifugation of mouse serum without activation of complement.
Leonard EJ; Skeel A
Mol Immunol; 1983 Jun; 20(6):589-95. PubMed ID: 6410183
[TBL] [Abstract][Full Text] [Related]
34. Dialysate temperature and complement activation.
Maggiore Q; Enia G; Catalano C; Mundo A; Misefari V
Contrib Nephrol; 1987; 59():72-9. PubMed ID: 3442988
[No Abstract] [Full Text] [Related]
35. Preparation and characterization of monoclonal antibodies against the fifth component of rabbit complement (C5).
Giclas PC; Baker SL; Gillespie ML; Wilcox C
J Immunol Methods; 1987 Dec; 105(2):201-9. PubMed ID: 3693908
[TBL] [Abstract][Full Text] [Related]
36. [Validity of the granulocyte aggregation test for the evaluation of complement activation in the adult respiratory distress syndrome].
Ortolani O; Conti A; Minale F; Imperatore R; Mazzarella L
Boll Soc Ital Biol Sper; 1985 Aug; 61(8):1207-14. PubMed ID: 4063110
[No Abstract] [Full Text] [Related]
37. Complement component C5: engineering of a mutant that is specifically cleaved by the C4-specific C1s protease.
Ogata RT; Low PJ
J Immunol; 1995 Sep; 155(5):2642-51. PubMed ID: 7650393
[TBL] [Abstract][Full Text] [Related]
38. Studies on the polymorphism of the fifth component of complement in laboratory mice.
Lynch DM; Kay PH
Exp Clin Immunogenet; 1995; 12(4):253-60. PubMed ID: 8919358
[TBL] [Abstract][Full Text] [Related]
39. Complement-derived peptide mediators of inflammation.
Jose PJ
Br Med Bull; 1987 Apr; 43(2):336-43. PubMed ID: 3319032
[No Abstract] [Full Text] [Related]
40. Quantitation of membrane biocompatibility.
Colton CK
Contrib Nephrol; 1987; 59():110-25. PubMed ID: 3502085
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
